TORRE, FRANCESCO
 Distribuzione geografica
Continente #
EU - Europa 4.799
AS - Asia 176
SA - Sud America 31
NA - Nord America 19
AF - Africa 6
Totale 5.031
Nazione #
IT - Italia 4.796
SG - Singapore 97
CN - Cina 40
VN - Vietnam 30
BR - Brasile 20
US - Stati Uniti d'America 13
AR - Argentina 7
MX - Messico 5
HK - Hong Kong 3
IQ - Iraq 3
MA - Marocco 2
PY - Paraguay 2
BD - Bangladesh 1
CA - Canada 1
DE - Germania 1
EC - Ecuador 1
ET - Etiopia 1
GA - Gabon 1
IN - India 1
KE - Kenya 1
MD - Moldavia 1
NL - Olanda 1
PE - Perù 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 5.031
Città #
Genova 3.013
Genoa 1.070
Rapallo 438
Vado Ligure 270
Singapore 24
Beijing 12
Ho Chi Minh City 10
Ashburn 9
Bordighera 5
Hanoi 4
Mexico City 4
Da Nang 3
Hong Kong 3
Tianjin 3
Bình Dương 2
Quảng Ngãi 2
São Paulo 2
Addis Ababa 1
Al Kazimiyah 1
Amsterdam 1
Asunción 1
Barbacena 1
Bengaluru 1
Biên Hòa 1
Bragado 1
Brasília 1
Bắc Giang 1
Bắc Ninh 1
Cabo Frio 1
Cachoeirinha 1
Campinas 1
Cantanhede 1
Casablanca 1
Charata 1
Cotia 1
Dallas 1
Denver 1
Durban 1
Encarnación 1
Esmeraldas 1
Florianópolis 1
Ipaussu 1
La Rioja 1
Libreville 1
Lima 1
Limeira 1
Lomas de Zamora 1
Londrina 1
Los Angeles 1
Lấp Vò 1
Mosul 1
Nairobi 1
New York 1
Ninh Bình 1
Nossa Senhora da Glória 1
Nova Santa Rita 1
Nuremberg 1
Recife 1
Resistencia 1
Rio Grande da Serra 1
Riyadh 1
Rizhao 1
San Miguel 1
Santos 1
Santos Lugares 1
Sarandi 1
Thái Bình 1
Tlajomulco de Zúñiga 1
Tongi 1
Toronto 1
Venha-Ver 1
Vĩnh Long 1
Totale 4.929
Nome #
Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. 206
A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? 203
Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents 202
Circadian secretion of melatonin and thyrotropin in hospitalized aged patients. 162
Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness? 161
Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity. 158
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. 152
Clinical implications of mutations in the hepatitis B virus genome. 146
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 145
Antiviral activity of amantadine in elderly patients with chronic hepatitis C 144
Clearance kinetics of hepatitis C virus under different antiviral therapies. 139
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden 136
Interferon retreatment in chronic hepatitis C: wich patients to choose, and what schedule to use 134
Effects of pyridostigmine, corticotropin-releasing hormone and growth hormone-releasing hormone on the pituitary-adrenal axis and on growth hormone secretion in dementia. 133
Monotherapy with Pegylated Interferon Alpha-2a in Hemodialyzed Patients with Chronic Hepatitis C 128
Evolution of wild-type and precore mutant HBV infection after liver transplantation. 126
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. 126
Continuous lamivudine treatment in an OLT patient despite the appearance of HBV resistant strain: longitudinal analysis. 125
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 122
A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy 119
TT virus infection in haemodialysis patients 117
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 117
Elevations in ALT levels late the course of antiviral therapy in HCV-RNA negative patients are associated with virological relapse 115
Prospective evaluation of primary infection due to HCV, HGV or TTV in children with newly diagnosed neoplasia. 115
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C 115
Chronic hepatitis C. New therapeutic strategies. 115
Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant 114
Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. 113
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. 111
Amantadine: a different approach. 110
Hepatitis B virus variants with core gene deletions in the evolution of chronic hepatitis B infection. 110
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 110
Novel immunoassay for the detection of hepatitis B surface 'escape' mutants and its application in liver transplant recipients. 105
Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. 103
Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. 97
Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients 94
Evaluation of a new hepatitis C virus sequecing assay as a routine method for genotyping 90
Sex hormones, gonadotropins and prolactin in male epileptic subjects in remission: role of the epileptic syndrome and of antiepileptic drugs. 84
Erythrocytes cell wall defects correlate with the stage of liver cirrhosis 82
Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. 68
Totale 5.052
Categoria #
all - tutte 14.714
article - articoli 14.714
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.428


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021155 0 0 0 0 0 22 11 29 23 31 21 18
2021/2022453 13 26 27 46 17 42 31 112 21 56 14 48
2022/2023536 59 58 7 45 81 90 3 48 86 5 48 6
2023/2024224 7 37 3 31 22 34 5 8 13 1 28 35
2024/2025729 30 43 11 54 96 57 59 150 17 26 80 106
2025/2026531 177 30 44 76 177 27 0 0 0 0 0 0
Totale 5.052